A Comparative Study on the Effect of Duloxetine Hydrochloride, Venlafaxine Hydrochloride, and Pregabalin on the Sensory Symptoms in Patients with Diabetic Polyneuropathy

Document Type : Original Article (s)

Authors

Abstract

Background: Peripheral neuropathic pain is a common disorder in patients with diabetes mellitus, which causes significant disability. Various treatments for this disorder have been proposed. This study aimed to find the best medicine for treating these patients (in short-term pain relief) via a comparison between duloxetine, venlafaxine, and pregabalin.Methods: 115 patients with diabetic polyneuropathy participated in this study. Patients were randomly divided into three groups of duloxetine (60 mg daily), venlafaxine (37.5 mg daily), and pregabalin (300 mg daily). At the end of the sixth weeks, pain severity and duration (hours per day) were evaluated and compared in three groups.Findings: The severity of pain after 6 weeks of treatment in the duloxetine group was significantly lower than the other groups (P = 0.030). However, the mean difference in pain intensity in the three groups was reduced, but there was no statistically significant difference (P = 0.174). Regarding the duration of pain, it was found that after the treatment, the duration of pain was not significantly different between the groups (P < 0.050).Conclusion: There was no difference in the results of treatment with duloxetine, venlafaxine, and pregabalin in reducing pain in patients with diabetic polyneuropathy. Therefore, one of the drugs can be prescribed according to the conditions of the patient.

Keywords

References

  1. Rao N, Rathi M, Sharma A, Ramachandran R, Kumar V, Kohli HS, et al. Pretransplant HbA1c and Glucose Metabolism Parameters in Predicting Posttransplant Diabetes Mellitus and Their Course in the First 6 Months After Living-Donor Renal Transplant. Exp Clin Transplant 2017. [Epub ahead of print].
  2. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care 2008; 31(Suppl 2): S255-S261.
  3. NeamTu MC, Avramescu ET, Marcu IR, Turcu-Stiolica A, Boldeanu MV, NeamTu OM, et al. The correlation between insulin-like growth factor with glycemic control, glomerular filtration rate, blood pressure, hematological changes or body mass index in patients with type 2 diabetes mellitus. Rom J Morphol Embryol 2017; 58(3): 857-61.
  4. Smith AG, Russell J, Feldman EL, Goldstein J, Peltier A, Smith S, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006; 29(6): 1294-9.
  5. Booya F, Bandarian F, Larijani B, Pajouhi M, Nooraei M, Lotfi J. Potential risk factors for diabetic neuropathy: A case control study. BMC Neurol 2005; 5: 24.
  6. Hunt D. Using evidence in practice. Foot care in diabetes. Endocrinol Metab Clin North Am 2002; 31(3): 603-11.
  7. Dyck PJ, Thomas PK. Diabetic neuropathy. Philadelphia, PA: Saunders, 1999.
  8. Feldman EL, Russell JW, Sullivan KA, Golovoy D. New insights into the pathogenesis of diabetic neuropathy. Curr Opin Neurol 1999; 12(5): 553-63.
  9. Olaleye D, Perkins BA, Bril V. Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diabetes Res Clin Pract 2001; 54(2): 115-28.
  10. Jensen PG, Larson JR. Management of painful diabetic neuropathy. Drugs Aging 2001; 18(10): 737-49.
  11. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47(2): 123-8.
  12. Gore M, Brandenburg N, Hoffman D, Tai K. Pain severity affects perceived health status in patients with diabetic peripheral neuropathy. Proceedings of the ISPOR 9th Annual International Meeting; 2004 May 16-19; Arlington, VA, USA.
  13. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002; 18(6): 350-4.
  14. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60(1): 108-11.
  15. White AG, Birnbaum HG, Mareva MN, Henckler AE, Grossman P, Mallett DA. Economic burden of illness for employees with painful conditions. J Occup Environ Med 2005; 47(9): 884-92.
  16. Haanpaa M. Treatment of painful diabetic polyneuropathy. Duodecim 2014; 130(12): 1235-42. [In Finnish].
  17. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116(1-2): 109-18.
  18. Razazian N, Baziyar M, Moradian N, Afshari D, Bostani A, Mahmoodi M. Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial. Neurosciences (Riyadh) 2014; 19(3): 192-8.
  19. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004; 63(11): 2104-10.
  20. Roy MK, Kuriakose AS, Varma SK, Jacob LA, Beegum NJ. A study on comparative efficacy and cost effectiveness of Pregabalin and Duloxetine used in diabetic neuropathic pain. Diabetes Metab Syndr 2017; 11(1): 31-5.
  21. Happich M, Schneider E, Boess FG, Wilhelm S, Schacht A, Birklein F, et al. Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational study. Clin J Pain 2014; 30(10): 875-85.
  22. Johnston SS, Udall M, Cappelleri JC, Johnson BH, Shrady G, Chu BC, et al. Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine. Am J Health Syst Pharm 2013; 70(24): 2207-17.
  23. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110(3): 628-38.
  24. Richter RW, Portenoy R, Sharma U, LaMoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebo-controlled trial. J Pain 2005; 6(4): 253-60.
  25. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110(3): 697-706.
  26. Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67(8): 1411-20.
Journal of Isfahan Medical School
Volume 35, Issue 462 - Serial Number 462
November and December 2018
Pages 1885-1891

Files

History

  • Receive Date: 21 October 2017
  • Revise Date:
  • Accept Date: 06 April 2022

Share

How to cite

Statistics